4 Top Market Picks Ready to Breakout (NASDAQ:GTXI, NASDAQ:MDVN, NASDAQ:ADMP, OTCMKTS:RHHBY)
February 05, 2014 at 12:30 PM EST
New York, NY -- (SBWIRE) -- 02/05/2014 -- GTx, Inc. (NASDAQ:GTXI) reported EPS of -0.715. For the Current Fiscal year, the company is expected to report EPS of -0.67. For the Next Quarter and Next Year, the company is expected to report EPS of -0.12 and -0.37 respectively. At Current Market Price, GTXI is in distance of -7.45% from its 50-day Moving Average price of $1.7936 and -21.44% from its 200-day Moving Average price of $2.1131. GTx, Inc. is a biopharmaceutical company. The Company is developing selective androgen receptor modulators (SARMs) , a drugs with the potential to prevents and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss).
